Vaccinex stock trades flat at USD 1.00 after a thin session

Vaccinex stock (VCNX) stood at USD 1.00 on the OTC Markets on September 23, 2026, unchanged from the prior close. The company had a market capitalization of USD 2,676,637, while its 52-week range extended from USD 0.31 to USD 1.50.

Yearly range remains wide

At USD 1.00, the share price was 33.33 percent below the 52-week high of USD 1.50 and USD 0.69 above the yearly low. That spread matters because the stock is trading near the midpoint of a wide range rather than close to either extreme.

Trading activity also remained limited in the September 23 snapshot. Volume was 291 shares, compared with an average volume of 1,203 shares, a difference of 75.81 percent. The comparison points to a market in which individual transactions can have a visible effect on the quote.

Clinical pipeline drives the story

Vaccinex is a clinical-stage biotechnology company developing biological therapies for cancer, neurodegenerative disorders and autoimmune diseases. Its lead candidate is pepinemab, a humanized monoclonal antibody that has been studied across conditions including Huntington's disease, Alzheimer's disease and head and neck cancer.

The investor page lists Vaccinex's 2025 annual financial results on April 29, 2026, and records a USD 60 million financing agreement for a Phase 2b pepinemab trial in Alzheimer's disease dated December 23, 2025. Those milestones put the company's valuation in the context of clinical development funding rather than commercial product revenue. The company also lists VX5, an antibody targeting CXCL13, as a preclinical program.

USD 1.00 marks the reference level

Vaccinex stock stood at USD 1.00 on the OTC Markets on September 23, 2026. With a market capitalization of USD 2,676,637 and a 52-week high of USD 1.50, the current quote remains 33.33 percent below the yearly peak.